Management of Cardiac Disease in Cancer Patients Throughout Oncological Treatment: ESMO Consensus Recommendations

Management of Cardiac Disease in Cancer Patients Throughout Oncological Treatment: ESMO Consensus Recommendations

Published in 2020 – Ann Oncol (2020); 31(2): 171-190.

Authors: G. Curigliano, D. Lenihan, M. Fradley, S. Ganatra, A. Barac, A. Blaes, J. Herrmann, C. Porter, A. R. Lyon, P. Lancellotti, A. Patel, J. DeCara, J. Mitchell, E. Harrison, J. Moslehi, R. Witteles, M. G. Calabro, R. Orecchia, E. de Azambuja, J. L. Zamorano, R. Krone, Z. Iakobishvili, J. Carver, S. Armenian, B.Ky, D. Cardinale, C. M. Cipolla, S. Dent & K. Jordan

This ESMO consensus manuscript recommends best practices for the care of cancer patients exposed to potential cardiotoxic therapy, including chemotherapeutic agents, targeted therapies and radiotherapy. These guidelines define common cardiovascular toxicities related to anticancer therapy and provide suggested strategies for the prevention, detection and treatment of cardiotoxicity.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings